Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Table of Contents Jardiance (Empagliflozin) Product Category Diabetes & Heart Failure SGLT2 Inhibitor Generic Name or Biosimilar No Active Ingredient Empagliflozin Prescription Status Prescription-only Targeted Conditions Jardiance is approved to treat the following conditions: Type 2 Diabetes Mellitus (T2DM), to improve glycemic control Heart Failure with Reduced Ejection Fraction (HFrEF), to reduce the risk of cardiovascular death and hospitalization Chronic Kidney Disease (CKD), to slow progression and improve renal outcomes Off-Label Usage Some off-label uses being studied or prescribed include: Heart Failure with Preserved Ejection Fraction (now formally approved) Type 1 Diabetes (investigational
Scully T, Ettela A, LeRoith D, Gallagher EJ
The most successful strategy for maintaining GLP-1 results involves building the behavioral foundation during treatment
Intestinal microbiota in cardiovascular health and disease: JACC State-of-the-Art Review
Some municipalities offer drop-off locations
US$ 22.08
US$ 21.38
US$ 28.25
US$ 24.89
US$ 28.16
US$ 21.14
US$ 28.89
US$ 24.03
US$ 28.81
US$ 29.77
